StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

Investment analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a note issued to investors on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Up 2.3 %

Shares of LPCN stock opened at $5.44 on Friday. Lipocine has a 12-month low of $2.31 and a 12-month high of $7.15. The company has a market capitalization of $28.94 million, a PE ratio of -1.78 and a beta of 1.05. The firm has a 50 day moving average price of $4.45 and a two-hundred day moving average price of $3.46.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.11. The firm had revenue of $0.22 million for the quarter. As a group, research analysts expect that Lipocine will post -1.49 EPS for the current year.

Institutional Trading of Lipocine

A number of institutional investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in shares of Lipocine in the first quarter valued at approximately $54,000. Renaissance Technologies LLC raised its stake in Lipocine by 474.5% in the second quarter. Renaissance Technologies LLC now owns 81,006 shares of the specialty pharmaceutical company’s stock valued at $65,000 after purchasing an additional 66,906 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Lipocine by 524.6% in the first quarter. Goldman Sachs Group Inc. now owns 88,615 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 74,428 shares in the last quarter. Millennium Management LLC bought a new stake in Lipocine during the second quarter worth about $160,000. Finally, State Street Corp grew its stake in Lipocine by 7.5% during the first quarter. State Street Corp now owns 327,405 shares of the specialty pharmaceutical company’s stock worth $449,000 after buying an additional 22,788 shares in the last quarter. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.